Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial.
Bimatoprost
Hypotrichosis
Minoxidil
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
20
05
2023
accepted:
17
07
2023
revised:
13
07
2023
medline:
22
9
2023
pubmed:
30
7
2023
entrez:
30
7
2023
Statut:
ppublish
Résumé
Eyebrows are an important feature of facial identity and communications in human beings as well as an important eye defense shield from dust and foreign bodies. To compare the efficacy and safety between 0.01%, 0.03% bimatoprost and minoxidil 2% in gel formulations for eyebrow enhancement. Sixty eligible subjects were female or male, aged 18 years or older with eyebrow hypotrichosis, defined as either a Grade 1 or 2 on the Global Eyebrow Assessment (GEBA) scale. Patients were randomized into 3 groups using block randomization. Group a (20 patients) applied topical 0.03% bimatoprost gel once daily onto both eyebrows, group b (20 patients) applied topical 0.01% bimatoprost gel once daily onto both eyebrows while group c (20 patients) applied topical minoxidil 2% gel once daily onto both eyebrows. A significant improvement in GEBA score was reported in all the three groups after treatment (P ≤ 0.001); however, there was no statistically significant difference between the three groups (P1 = 0.091; P2 = 0.102; P3 = 0.663). Bimatoprost is equally efficacious as minoxidil in enhancement of eyebrows with a more favorable response produced by the 0.03% concentration.
Identifiants
pubmed: 37517060
doi: 10.1007/s00403-023-02679-2
pii: 10.1007/s00403-023-02679-2
pmc: PMC10514173
doi:
Substances chimiques
Bimatoprost
QXS94885MZ
Minoxidil
5965120SH1
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2635-2641Informations de copyright
© 2023. The Author(s).
Références
J Cosmet Dermatol. 2020 Jun;19(6):1404-1408
pubmed: 31541563
Dermatol Online J. 2014 Jun 15;20(6):
pubmed: 24945645
Eur J Ophthalmol. 2006 Mar-Apr;16(2):247-50
pubmed: 16703542
Cureus. 2018 May 21;10(5):e2666
pubmed: 30042917
Ophthalmology. 2001 Jun;108(6):1023-31; discussion 1032
pubmed: 11382623
J Cosmet Dermatol. 2020 Mar;19(3):714-719
pubmed: 31317662
J Drugs Dermatol. 2012 Jan;11(1):106-8
pubmed: 22206085
Surv Ophthalmol. 2001 May;45 Suppl 4:S361-8
pubmed: 11434939
Dermatol Surg. 2016 May;42(5):608-17
pubmed: 27124878
J Dermatol. 2014 Feb;41(2):149-52
pubmed: 24471459
Dermatol Surg. 2010 Sep;36(9):1361-71
pubmed: 20384750
Dermatol Surg. 2013 Jul;39(7):1079-87
pubmed: 23617229
Acta Derm Venereol. 2002;82(1):7-12
pubmed: 12013211
Adv Ther. 2001 May-Jun;18(3):110-21
pubmed: 11571823
J Drugs Dermatol. 2014 Jan;13(1 Suppl):s12-6
pubmed: 24385126
J Dermatol. 2012 Oct;39(10):865-6
pubmed: 22594928
Drug Des Devel Ther. 2018 Feb 22;12:365-372
pubmed: 29503529
J Am Acad Dermatol. 2001 Apr;44(4):721-3
pubmed: 11260563
Dermatol Surg. 2011 Jul;37(7):1057-9
pubmed: 21457389
Expert Opin Investig Drugs. 2017 Apr;26(4):515-522
pubmed: 28264599
Dermatol Surg. 2019 Dec;45(12):1549-1556
pubmed: 30913051
Dermatol Surg. 2010 May;36(5):638-49
pubmed: 20384751
Exp Dermatol. 2005 May;14(5):323-8
pubmed: 15854125